Entera Bio (NASDAQ:ENTX) Director Acquires $12,000.00 in Stock

Entera Bio Ltd. (NASDAQ:ENTX) Director Steven Rubin acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was purchased at an average cost of $1.20 per share, with a total value of $12,000.00. Following the acquisition, the director directly owned 10,000 shares of the company’s stock, valued at $12,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Entera Bio Stock Performance

ENTX stock opened at $1.50 on Friday. The company has a market cap of $68.79 million, a price-to-earnings ratio of -6.00 and a beta of 1.84. The business’s 50-day moving average is $1.67 and its two-hundred day moving average is $2.02. Entera Bio Ltd. has a fifty-two week low of $1.00 and a fifty-two week high of $3.22.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02. Equities analysts predict that Entera Bio Ltd. will post -0.28 earnings per share for the current year.

Institutional Investors Weigh In On Entera Bio

Institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC lifted its position in shares of Entera Bio by 243.0% in the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after acquiring an additional 28,322 shares in the last quarter. HighTower Advisors LLC raised its stake in Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after purchasing an additional 25,000 shares during the period. Jane Street Group LLC lifted its holdings in Entera Bio by 142.6% in the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after purchasing an additional 43,536 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after purchasing an additional 19,601 shares in the last quarter. Finally, Bessemer Group Inc. bought a new position in Entera Bio in the 2nd quarter worth approximately $268,000. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ENTX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Entera Bio in a report on Monday, February 9th. Finally, Wall Street Zen upgraded Entera Bio to a “sell” rating in a research report on Saturday, December 27th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Entera Bio currently has an average rating of “Hold” and a consensus target price of $10.00.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.